Abstract

Methionine adenosyltransferase (MAT) deficiency, characterized by isolated persistent hypermethioninemia (IPH), is caused by mutations in the MAT1A gene encoding MATαl, one of the major hepatic enzymes. Most of the associated hypermethioninemic conditions are inherited as autosomal recessive traits; however, dominant inheritance of hypermethioninemia is caused by an Arg264His (R264H) mutation. This mutation has been confirmed in a screening programme of newborns as the most common mutation in babies with IPH. Arg264 makes an inter-subunit salt bridge located at the dimer interface where the active site assembles. Here, it is demonstrated that the R264H mutation results in greatly reduced MAT activity, while retaining its ability to dimerize, indicating that the lower activity arises from alteration at the active site. The first crystallographic structure of the apo form of the wild-type MATαl enzyme is provided, which shows a tetrameric assembly in which two compact dimers combine to form a catalytic tetramer. In contrast, the crystal structure of the MATαl R264H mutant reveals a weaker dimeric assembly, suggesting that the mutation lowers the affinity for dimer-dimer interaction. The formation of a hetero-oligomer with the regulatory MATβV1 subunit or incubation with a quinolone-based compound (SCR0911) results in the near-full recovery of the enzymatic activity of the pathogenic mutation R264H, opening a clear avenue for a therapeutic solution based on chemical interventions that help to correct the defect of the enzyme in its ability to metabolize methionine.

Highlights

  • Methionine adenosyltransferase (MAT) deficiency (OMIM 250850) is the most common cause of isolated persistent hypermethioninemia (IPH), which has been established as an inborn error of metabolism (Gaull & Tallan, 1974)

  • We show that the activity of the R264H mutant can be restored to the levels found for the wild-type enzyme when the mutant is incubated with the quinolone compound SCR0911 or the regulatory subunit MAT V1

  • We report the first crystal structure of human apo MAT 1, which was solved at 2.3 Aresolution, revealing a tetrameric assembly

Read more

Summary

Introduction

Methionine adenosyltransferase (MAT) deficiency (OMIM 250850) is the most common cause of isolated persistent hypermethioninemia (IPH), which has been established as an inborn error of metabolism (Gaull & Tallan, 1974). In the central region of the wild-type MAT 1 dimer the MAT subunits interact through polar contacts, creating a salt bridge between Arg264 of one subunit and Glu of the other This interaction has been reported to be essential for dimerization and to be of importance for the formation of the active site (Chamberlin et al, 1997; Mato et al, 2001). We show that the activity of the R264H mutant can be restored to the levels found for the wild-type enzyme when the mutant is incubated with the quinolone compound SCR0911 or the regulatory subunit MAT V1 This discovery opens an opportunity for chemical intervention to alleviate this diseasecausing defect in catalysis

Protein expression
Site-directed mutagenesis
MATa1–MATb complex formation
Activity assay
Crystallization and data collection
Molecular docking
MAT sequence analysis
The crystal structure of tetrameric wild-type MATa1: an apo form
The crystal structure of the dimeric MATa1 R264H mutant
Can the loss of activity of R264H MATa1 be recovered?

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.